NTHI

NeOnc is a clinical-stage biopharma with no approved products and, by its own admission, no product revenue — the $40.0K FY2025 'revenue' is humanitarian-usage only and actually fell 51.8% YoY. The P/S of 2,631x is meaningless; there is no business to value on sales. What matters is the pipeline (NEO100 in a Phase 2a recurrent-glioma trial, NEO212 entering Phase 1) versus the cash to fund it, and that arithmetic is alarming. FY2025 net loss ballooned to $62.1M from $11.9M (–422%), operating cash flow was –$20.4M, and the company held just $58.7K in cash against $20.0M of current liabilities. Stockholders' equity is negative $17.5M and accumulated deficit is $112.8M.

The balance sheet is effectively insolvent: total assets of $2.82M cannot cover $20.3M of liabilities, and current assets of $1.39M are dwarfed by current liabilities of $20.0M. With ~$0.06M of cash and a ~$20M annual burn, the company is entirely dependent on external financing to keep the lights on — a classic going-concern setup that the MD&A all but states, warning of 'significant and increasing expenses and operating losses for the foreseeable future' and that it 'will not generate revenue from product sales unless and until' it obtains regulatory approval.